Inhibitors of the receptor tyrosine kinase (RTK) MET have been ineffective at treating cancer, possibly because of lack of knowledge that would allow selection of tumors likely to respond to this treatment. In contrast, specific epidermal growth factor receptor (EGFR) inhibitors have been used successfully against lung tumors displaying activating mutations in the kinase domain of EGFR. Recent publications describe a set of mutations causing MET exon 14 skipping, and importantly, several case reports describe objective responses to MET-targeting tyrosine kinase inhibitors in patients with such mutations. These observations suggest a novel therapeutic strategy for fighting cancer, especially in the lung. Exon 14 encodes the MET juxtamembrane domain targeted by mechanisms that negatively regulate receptor stability and activity. In this review, we describe the molecular mechanisms leading first to exon 14 skipping and then to activation of the MET receptor and how this process differs from that triggered by classical RTK-activating mutations in the kinase domain. We detail the clinical characteristics of patients carrying these mutations and the sensitivity of their tumors to MET inhibitors. Lastly, we discuss future challenges related to MET mutations in cancers, including patient screening and anticipating resistance to MET inhibitors.
MET is a receptor tyrosine kinase (RTK) produced predominantly in cells of epithelial origin. It is activated by its stromal ligand, hepatocyte growth factor (HGF), also called scatter factor (1) . HGF and MET are essential to embryonic development as knockout of either one affects epithelial organ, placenta, muscle, and neuron formation (2) (3) (4) (5) . Conditional knockout of MET in the lung has demonstrated its involvement in alveolar development (6) . In adults, the HGF-MET pair is involved in physiological processes such as epidermal healing and liver regeneration (7) (8) (9) .
The extracellular part of MET contains an N-terminal SEMA domain encompassing the a subunit and the first amino acids of the b subunit, followed by a plexin-semaphorin-integrin (PSI) domain and four immunoglobulin-like domains. The intracellular region contains a juxtamembrane domain, the tyrosine kinase domain, and a C-terminal tail ( Figure 1 ) (10) . MET interaction with its ligand favors its dimerization and autophosphorylation on two tyrosine residues of its catalytic domain (Y1234 and Y1235). Other tyrosine residues, located outside the kinase domain, are then phosphorylated, especially tyrosine 1003 in the juxtamembrane domain and tyrosines 1349 and 1356 in the C-terminal tail ( Figure 1 ) (11, 12) . The phosphorylated C-terminal residues allow recruitment of important effectors such as GRB2-associated binder-1 (GAB1), growth factor receptor-bound protein-2 (GRB2), SRC homology 2 domain containing (SHC), phosphoinositide 3 kinase (PI3K), SRC, signal transducer and activator of transcription 3 (STAT3), and phospholipase C-gamma (PLCc). This multisubstrate docking site plays a key role in MET-induced biological responses because its mutation in mice triggers phenotypes similar to those of MET-deficient mice (13) .
In parallel, downregulation of MET receptor activity is an essential process preventing receptor oversignaling. Interestingly, all the regulatory mechanisms evidenced so far target the juxtamembrane region of the cytoplasmic part of the receptor, encoded by exon 14.
Aberrant HGF-MET signaling is involved in tumorigenesis and metastasis. In many human cancers, overexpression of the genes encoding HGF and MET causes either paracrine or autocrine activation of the receptor and is associated with poor prognosis (14) (15) (16) (17) (18) (19) (20) . Massive synthesis of MET, leading to its ligandindependent activation, is notably related to amplification of its gene, which is observed in a small percentage (about 1% to 5%) of gastric and lung cancers (21) (22) (23) . Numerous MET mutations have also been described in various cancer types, including renal and lung cancers (24) . Recently, thanks to improved sequencing techniques, deletion of MET exon 14 has been evidenced in several tumor types, and a few patients with this kind of mutation are reported to have benefited from MET-targeting therapy. This review describes the various mutations known so far to cause deletion of MET exon 14 and the hypothetical functional consequences of such mutations. We also address the clinical data available on patients harboring MET exon 14 splice mutations.
MET Mutations Previously Identified in Cancers
More than 200 missense substitutions have been evidenced in the MET sequence in a variety of cancers (source: Catalogue of Somatic Mutations in Cancer, http://cancer.sanger.ac.uk/cos mic). A clear link between aberrant MET activation and cancer development in humans was established with the identification of mutations in the MET kinase domain associated with hereditary renal papillary carcinoma (25) . Later, somatic mutations located in the MET kinase domain were identified in renal and upper aerodigestive tract cancers. These mutations, such as D1228N, Y1235D, and M1250T, lead to constitutive MET kinase activity, favor ligand-induced MET activation, or induce its recycling to the membrane (26, 27) (Figure 1) . Consistently, transgenic mice with MET mutations in the kinase domain develop several types of cancer (lymphomas, carcinomas, and sarcomas) (28) .
In contrast, the mutations found in lung tumors do not lie within the kinase domain, and their functional consequences remain elusive. They can be divided into two groups. The first consists of mutations within the SEMA domain in the extracellular part of MET, including the N375S mutation. This particular mutation might simply reflect polymorphism. Indeed, it is particularly frequent in the East Asian population in the germline, and it does not seem associated with lung cancer susceptibility (29) . The second group comprises missense mutations located in exon 14, including R970C, P991S, and T992I (respectively R988C, P1009S, and T1010I in a longer isoform of MET) ( Figure 1 ) (30) . These mutations are thought to occur in 3% to 10% of lung cancers (29) (30) (31) (32) Figure 1 . Schematic representation of MET, illustrating its main functional domains including the SEMA domain shared between the two chains, a plexin-semaphorinintegrin (PSI) domain, four IPT domains (an immunoglobin-like fold shared by plexins and transcription factors), the juxtamembrane domain encoded by exon 14, the kinase domain, and the multisubstrate docking site. The phosphorylated residues and main missense mutations affecting the SEMA, juxtamembrane, and kinase domains are shown. NSCLC ¼ non-small cell lung cancer; RCC ¼ renal cell carcinoma.
MET kinase activation (31, 33, 34) . We recently demonstrated that the R970C mutation favors MET proteolytic cleavages by calpain in lung cancer cells, leading to generation of an intracellular fragment of about 45 kDa. Ectopic expression of this fragment promotes epithelial cell migration, suggesting an active role in HGF-induced responses (Montagne et al., unpublished data). Yet whether the juxtamembrane mutations of MET actually play a role in tumorigenesis remains controversial: They might reflect simple polymorphism as they have also been found in the germline and do not lead to MET kinase activation (a hallmark of tumor-promoting mutations) (31) . Therefore, for each missense mutation located in exon 14, further functional evidence is needed. It is notably necessary to demonstrate its transforming capacity and mechanism of action in order to assess its functional relevance to cancer pathogenesis.
Importantly, because the MET missense mutations inside the juxtamembrane domain found in lung cancer do not lead to kinase activation, their action cannot be countered by tyrosine kinase inhibitors (TKIs). This contrasts with epidermal growth factor receptor (EGFR) mutations reported in lung cancer, which induce constitutive tyrosine kinase activation and are associated with sensitivity to EGFR TKIs.
Landscape of the Mutations Leading to Exon 14 Deletion
In 2003, Ma et al. suggested for the first time that mutations in the intron upstream from MET exon 14 might be responsible for mRNA splicing and exon skipping. In a study where the MET genomic DNA of 32 small cell lung cancer (SCLC) tumor samples was sequenced by conventional molecular methods such as Sanger sequencing, the investigators discovered in two tumors a two-basepair insertion in the intron upstream from exon 14, suspected of inducing its alternative splicing (34) . This hypothesis was validated in a second study, by identification of inframe exon 14 skipping in one out of 127 cases of non-small cell lung cancer (NSCLC) (35) . The link between exon skipping and somatic mutations affecting splice junctions flanking exon 14 was demonstrated in 2006 in two adenocarcinoma tissues and the NSCLC cell line H596 by comparing genomic DNA and cDNA sequences (36) . Since then, a few additional somatic alterations affecting exon 14 have been described, but the rate and functional consequences of these mutations in lung cancers have not been characterized (37) (38) (39) .
Recently, profiling of 230 lung adenocarcinomas by wholeexome sequencing combined with mRNA sequencing revealed a relatively high rate of somatic mutations (about 3%), leading to exon 14 skipping in lung cancer (40) . Last year, molecular profiling of 38028 tumor samples by targeted next-generation sequencing (NGS) revealed the high diversity of MET exon 14 alterations across advanced cancers of various origins, including lung cancers and also gastric, colorectal, and brain cancers, although at a lower rate (41) . More than 160 different alterations affecting MET exon 14 were described (41) (42) (43) . These mutations are point mutations, deletions, insertions, or complex mutations (indels) that all affect conserved sequences of splice donor or acceptor sites. At the 5' end of the exon, most of the alterations are deletions, insertions, and indels affecting the splice acceptor, the branch point, or the polypyrimidine tract. At the 3' end, they are mostly point mutations affecting the splice donor site (Figure 2A ) (41) . All these alterations potentially lead to exon 14 skipping.
The Juxtamembrane Domain Encoded by Exon 14 Drives Negative Regulation of MET
Although mutations leading to exon 14 deletion were not studied until recently, the negative regulation driven by the region encoded by the exon has been known since the 1990s. In mouse liver and kidney, alternative splicing of exon 14 has been described (exon 14 in transcript ID ENSMUST00000115443, also referenced as exon 15 in transcript ID ENSMUST00000115442). This rare alternative splicing event leads to a 141-basepair deletion predicted to result in a 47-amino-acid in-frame deletion in the juxtamembrane region of the cytoplasmic part (44) . In normal human tissues, no such alternative splicing event has yet been described. The possibility that exon 14 deletion could promote tumorigenesis was suggested already by the observation that mouse fibroblasts expressing a MET-exon-14-deleted variant displayed transforming phenotypes and formed tumors when grafted in immunodeficient mice (45, 46) . Since then, several negative regulatory sites have been characterized in the juxtamembrane domain encoded by this exon.
The first negative regulatory mechanism found to target the juxtamembrane region was phosphorylation of serine 985. This phosphorylation impairs proper phosphorylation of the MET tyrosine residues and can thus control cell responsiveness to HGF (47) . Ser985 is phosphorylated by protein kinase C (PKC) and dephosphorylated by protein phosphatase 2A (PP2A) (48) . After liver injury, ligand-dependent activation of the MET kinase, required for tissue regeneration, correlates with a decrease in Ser985 phosphorylation (49) . This suggests an involvement of Ser985 in regulating MET activity in a physiological process. Deletion of exon 14 may confer insensitivity to MET inhibitory signals conveyed by PKC, increasing the probability of total MET activation ( Figure 2B ).
The second residue crucial to MET downregulation identified in the juxtamembrane domain was tyrosine 1003. Following MET activation, Tyr1003 phosphorylation triggers recruitment of the E3 ubiquitin ligase CBL (Casitas B-lineage lymphoma), via an interaction with the tyrosine kinase binding domain (TKB) of the latter. This leads to MET ubiquitination (50) . Although GRB2 bound to the MET C-terminal multidocking site has also been found to contribute, indirectly, to CBL recruitment, mutation of Tyr1003 alters the interaction of MET with CBL and subsequent MET ubiquitination. Most importantly, MET mutated at 1003 displays higher stability and a greater transforming capacity than the wild-type version. This sheds some light on the gain of motility function observed with a Tyr 1003 mutant generated in a previous study (51) . A more detailed study has highlighted that the motif for CBL recruitment is DpYR and that mutating any one of its three residues impairs MET ubiquitination and leads to formation of foci suggestive of cell transformation (52) . Remarkably, mutating Tyr 1003 does not impair clathrindependent MET internalization (which occurs following indirect CBL recruitment via GRB2), but even though the mutant is internalized, the absence of ubiquitination prevents its efficient degradation ( Figure 2B ) (53) .
CBL can act as a tumor suppressor by downregulating RTK activity (54) . Interestingly, CBL mutations and loss of heterozygosity have been detected in lung cancers (55) . Although these alterations were not found in combination with TP53 or KRAS (Kirsten rat sarcoma) mutations, they can occur concomitantly with MET or EGFR mutations, possibly favoring RTK activity. In parallel to RTK downregulation by CBL, it has been shown that CBL is reciprocally downregulated by MET and EGFR (56) gastric carcinoma cell lines were found to drive downregulation of CBL. The level of CBL was restored by inhibiting MET pharmacologically. Similarly, activated EGFR induced the downregulation of CBL. This further supports a connection between CBL, MET, and EGFR in lung malignancies. The third regulatory site on exon 14 is a caspase site involved in MET processing during apoptosis. Upon stress induction and in the absence of ligand, the MET receptor is first cleaved at a consensus caspase site in its C-terminal tail. This initial cleavage is followed by a second one, at aspartic acid 1002 within an ESVD motif. These cleavages generate a 40 kDa cytoplasmic C-terminal fragment (p40 MET) containing the tyrosine kinase domain (57, 58) . As a result of caspase cleavages, the level of full-length MET receptor decreases strongly during apoptosis, and separation of the extracellular ligand-binding domain from the kinase domain creates fragments that are no longer able to be activated by the ligand. Furthermore, caspase cleavages not only inactivate the receptor but also convert it to a pro-apoptotic fragment able to amplify cell death by favoring mitochondrial permeabilization (59 Figure 2B ) (60) .
Other, less characterized negative regulatory mechanisms might involve the region encoded by exon 14. For instance, the ESVDYR motif of the juxtamembrane region can interact with the phosphatase protein tyrosine phosphatase-soluble (PTP-S) (61) , and the juxtamembrane domain contains a putative Pro, Glu, Ser, Thr (PEST) sequence, classically associated with proteolysis (46) . In summary, exon 14 contains various sites participating in regulatory mechanisms that prevent MET activation or convert MET to a pro-apoptotic actor. Deletion of this exon may give cells a survival advantage. The relative contribution of each regulatory site deletion to the transforming phenotype observed in exon-14-deleted MET cancer cells has not been studied so far. Although mutation of Tyr1003 has been proved to confer transforming properties, the low prevalence of Tyr1003 mutations compared with exon 14 deletions suggests that exon 14 deletion provides advantages beyond decreased MET ubiquitination.
Strikingly, the recent discovery of exon 14 deletion as a biomarker for MET-targeted therapy takes us back to the initial discovery of MET: The MET proto-oncogene was first identified in the fusion protein translocated promoter region-MET fusion protein (TPR-MET), generated in a chemical mutational screen (62) . The TPR part of the fusion was found to cause its constitutive dimerization, inducing activation of the MET kinase domain. Whereas TPR was fused with the region immediately following MET exon 14, re-introduction of exon 14 into TPR-MET strongly reduced its oncogenic activity. This highlights the importance of exon 14 in downregulating MET activity (63) .
The cell lines NCI-H596, derived from an NSCLC, and Hs746T, derived from a gastric carcinoma, display MET exon 14 skipping (36, 64) . In these cell models, this skipping is due to intronic mutations located in the splice acceptor site in Hs746T cells and in the splice donor site in NCI-H596 cells. Other genetic alterations have also been identified in these two cell lines: Hs746T cells display amplification of the MET gene, and H596 cells have an activating mutation in PI3KCA (65) . In vitro, treatment of Hs746T cells with the MET TKI crizotinib (a multitarget TKI of MET, ALK, and ROS1) inhibits PI3K and MAPK signaling and blocks cell proliferation. Because this cell line displays both MET gene amplification and exon 14 mutations, sensitivity to the MET inhibitor cannot be attributed with certainty to exon 14 skipping. In H596 cells, because of the association of MET exon 14 skipping and the PI3KCA mutation, combination of with crizotinib and a PI3K inhibitor was required to get similar results (66) . These data highlight the lack of cellular models derived from patients to study the exon 14 skipping without other concomitant alterations. Interestingly, the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system recently allowed genome editing of HEK293 cell lines to create MET exon 14 deletion. These mutated cell lines displayed higher MET expression, enhanced MET phosphorylation, and prolonged activation of the downstream signaling pathways, the expected consequences of the negative regulatory sites deletion. In addition, exon 14 deleted cell lines are more sensitive to the MET inhibitor crizotinib than their wild-type counterpart (67) .
Clinical Characteristics of Patients With Exon-14-Deleted Tumors
Exon 14 splice mutations have been observed in various tumor types, including lung (2.7%), gastric (7.1%), and colorectal cancers (0% to 9.3%), brain glioma (0.4%), and rarely other malignancies (soft tissue sarcoma, urothelial carcinoma, skin merkel cell carcinoma, adrenal gland cortical carcinoma, kidney renal cell carcinoma, liver hepatocellular carcinoma) (41) (42) (43) . Among lung cancers, the exon 14 mutation rate seems particularly high in adenocarcinoma (2.6% to 3.2%) (41, 43, 68, 69) , pulmonary sarcomatoid tumors (2.6% to 31.8%) (39, 43, 66, 68, 69) , and adenosquamous carcinoma (4% to 8.2%) (43, 68) . MET exon 14 mutations have also been observed at lower frequency in squamous cell carcinoma, large cell carcinoma, NSCLC NOS, and small cell carcinoma (41, (68) (69) (70) .
The impact of MET exon 14 mutations on survival has not yet been extensively studied. Tong et al., however, performed a survival analysis of 687 patients with untreated NSCLC at various stages. Multivariable analysis revealed that MET exon 14 mutation, MET high-level amplification, and advanced stage were independent poor prognosis factors (69) .
Clinical characteristics associated with MET exon 14 mutations are still poorly known. MET exon 14 mutations seem to be less frequent in Asian patients with lung adenocarcinoma (0.9% to 2.2%) than in Caucasian patients (71) (72) (73) . Shrock et al. reported the clinical characteristics of 298 lung cancer patients harboring MET exon 14 mutations and found a high proportion of women (60%) and elderly patients (median age ¼ 73 years) (43) . Regarding smoking status, while a study found a lower proportion of never-smokers in MET exon 14 mutated patients compared with EGFR-mutated patients, another study found no difference in smoking history between MET exon 14 mutated and wild-type patients (68, 69) . Exon 14 splice mutations have usually been detected in multiplex assays screening for many molecular alterations (36, 37, (41) (42) (43) 66, (74) (75) (76) (77) (78) . In most cases, MET exon 14 splice mutations were found not to coexist with other known driver molecular alterations such as EGFR, KRAS, and HER2 mutations or ALK, ROS1, and RET rearrangements. However, mouse double minute chromosome 2 (MDM2) amplification, cyclin-dependent kinase 4 (CDK4) amplification, and EGFR amplification have been found to coexist with MET exon 14 mutations (43, 68) . More rarely, BRAF, KRAS, and PIK3CA mutations have been reported in association with MET exon 14 mutations (66, 68, 69) .
In an NGS-based assay, MET gene copy gain was determined, considering the gain to be high when the MET-to-chromosome 7 (CEP7) ratio reached 3:1, and low when this ratio was greater than 1 and less than 3. Using these boundaries, high-level and low-level MET copy gain were observed, respectively, in 21% and 29% of patients with an exon 14 mutation (68). Interestingly, the MET/CEP7 ratio was statistically significantly higher in stage IV exon-14-mutated NSCLC than in stage I-III with an exon 14 mutation or stage IV without this mutation.
Using FISH, Tong et al. found MET copy number alterations, defined as five or more MET signals, MET/CEP7 ratio of 2 or higher, or clustered MET signals, to be statistically significantly associated with exon 14 mutations (69). In two independent studies, MET gene copy gain determined by NGS was found in 15% to 21% of MET exon 14 mutated tumor samples (43, 68) .
As MET exon 14 skipping prevents MET degradation, it is anticipated that exon 14 skipping leads to increased MET expression. Accordingly, Tong et al. found by immunohistochemistry (IHC) a statistically significant association between exon 14 mutation and the intensity of MET staining (69) . MET overexpression in exon-14-mutated NSCLC was observed even in absence of concurrent MET copy gain (69) . Inversely, at least one METexon 14 mutation was detected in a tumor sample showing very low levels of MET expression (68) .
Treatment of Patients With MET-Exon 14 Deleted Tumors
MET is already viewed as a potential target for therapy in various cancers, and more than 300 clinical trials are ongoing to evaluate the safety and/or efficacy of pharmacological MET inhibitors and antibodies directed against MET or HGF (Supplementary Table 1 , available online). Although trials evaluating the therapeutic use of MET inhibitors in unselected populations have yielded disappointing results, recent data suggest that MET inhibitors such as crizotinib, a multitarget TKI of MET, anaplastic lymphoma kinase (ALK), and ROS1, already approved for the treatment of ALK-positive lung cancers, might be active against tumors displaying MET gene amplification (79) . Studies are in progress to evaluate the action of other MET TKIs such as capmatinib (a selective ATP-competitive inhibitor) against METderegulated tumors. Thus, several therapeutic options have been available for treating patients with MET exon 14 splice mutations in the context of clinical trials (see Supplementary Table  1 , available online) or off-label prescription.
Several patients with MET exon 14 splice mutations are reported to have been treated with a MET TKI (41, 43, 66, 68, 70, 71, (74) (75) (76) (77) (78) 80, 81) . The characteristics of these patients are detailed in Table 1 . All the patients had lung cancer (mostly adenocarcinoma), except for one case of hystiocytic sarcoma (41) . The MET inhibitors included crizotinib , capmatinib, and cabozantinib, another multitarget TKI active against MET. Most of these cases were reported to achieve objective response. Preliminary results from a phase I clinical trial (PROFILE 1001) reported five objective responses out of 15 MET exon 14 mutated NSCLC patients treated with crizotinib (82) . Although interpretation of these data is restricted by the small number of patients and selection bias, dramatic and prolonged responses were reported, in line with the known efficacy of targeted therapies in other models of oncogene-addicted tumors.
It is worth noting that objective responses to MET TKI were observed in both smokers and never-smokers, in patients with adenocarcinoma, squamous cell carcinoma, pulmonary sarcomatoid carcinoma, and sarcoma patients with or without MET copy gain, and in patients with an impaired p53 pathway. Surprisingly, an NSCLC patient with both MET exon 14 and PIK3CA mutations displayed a partial response to crizotinib (75) , in sharp contrast to in vitro data showing resistance to crizotinib of cell line H596 displaying both MET exon 14 and PIK3CA mutations (66) . These encouraging preliminary results have prompted tremendous efforts to design and launch clinical trials evaluating various MET TKIs in the treatment of METmutant cancers, including MGCD265 (NCT02544633), capmatinib (NCT02414139), MGCD516 (NCT02219711), and crizotinib (NCT02034981) (see Supplementary Table 1 , available online).
Prospects
The Efficacy of MET-Targeting Therapies Is Associated With Oncogene Addiction (85) . Autocrine/paracrine HGF production is also observed in various cancers and associated with poor prognosis. In the glioblastoma model, HGF expression has been shown to contribute to MET oncogene addiction and to predict response to MET inhibitors (86) . Additionally, germline MET mutations in the kinase domain have proved predictive of the response to foretinib, a dual MET/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, in papillary renal carcinomas (87) . Thus, MET addiction and consequently sensitivity to MET inhibitors may involve various categories of patients through several distinct mechanisms.
Future TKI Treatments for Exon-14-Mutant Tumors
The majority of RTK mutations known to lead to oncogene addiction are activating mutations within the tyrosine kinase domain. Yet many other mutations affect other functional domains, but their functional consequences remain elusive in most cases. In the case of MET exon 14 mutations, the mechanism of receptor activation is original because it involves the loss of negative regulations. This mode of action is likely more effective because the juxtamembrane domain is the target of several negative regulatory mechanisms. It is still unclear whether HGF stimulation is required for stimulation of the exon-14-deleted MET receptor. The same question can be asked about some mutations in the kinase domain because in cell lines they sensitize MET to stimulation by HGF instead of inducing ligand-independent stimulation (88) . Ultimately, like the kinase domain mutations and MET gene amplification, exon 14 mutations lead to activation of MET and of its downstream signaling, which increases tumor sensitivity to TKIs.
It is worth noting that the MET exon 14 splice mutations could preferentially occur in lung cancer patients who were smokers, in striking contrast to EGFR mutations or ALK rearrangements. This may have functional consequences, as the smoking status is associated with a higher burden of mutations and decreased sensitivity to TKIs (through various mechanisms including expression of reactive oxygen species and increased TKI metabolism). Co-occurring mutations may also affect the sensitivity of MET-mutant tumors to MET TKIs, as highlighted by the lack of sensitivity of the PIK3CA and MET mutant cell line H596 to crizotinib. Frequent impairment of the p53 axis may reflect the high proportion of smokers among MET-exon-14-mutated patients and may hinder the apoptotic response induced by MET TKIs. Yet objective responses have been reported despite MDM2 amplification or a known TP53 mutation (41, 77, 80) . The fact that no other concurrent driver mutations have been found in MET-mutant tumors strengthens the hypothesis that the MET mutations are a key event for cancer cells.
Detecting Exon 14 Splice Mutations for Diagnosis
Because exon 14 splice mutations are present in a restricted number of patients, selecting all patients liable to benefit from MET-targeting therapy requires an efficient strategy for identifying these mutations. NGS is an attractive technology in this context as it is now widely implemented in molecular laboratories and allows comprehensive molecular profiling. The first challenge is to improve sequencing techniques to allow detection of all MET exon 14 splicing variants. This is illustrated by the fact that Liu et al. detected by whole-exome sequencing only three out of 10 mutations, while two more mutations were detected on a commercial targeted NGS panel and the remainder was detected by Sanger sequencing. Improved bioinformatic analysis is needed to detect mutations of various lengths and sequences (66 
Anticipating Acquired Resistances
Mechanisms of acquired resistance to TKIs in oncogeneaddicted models mostly involve kinase-domain mutations that restore affinity for ATP and/or impair affinity for TKIs (89) . In this line, mutation of the MET residues D1228 and Y1230 within the kinase domain was described to induce resistance to MET inhibitors in cellular models of MET oncogene addiction (90, 91) . Interestingly, a MET exon 14 mutated NSCLC patient who had progressive disease under crizotinib was shown to harbor a second MET mutation (D1228N) that affects the kinase domain (92) . A second case of MET kinase domain mutation (Y1230C) detected in a tumor sample obtained after progression on crizotinib in a MET exon 14 mutated NSCLC patient suggests that additional MET mutations may be a key mechanism of resistance to MET TKIs (93) . Other mechanisms of resistance may include MYC alterations, ATP binding cassette subfamily B member 1 (ABCB1) overexpression, KRAS mutation, HER2 amplification, EGFR activation, or BRAF fusion, all of which have been implicated in resistance to MET TKIs in nonmutated METaddicted cancers (90, (94) (95) (96) (97) (98) . Cancer cell lines modeling acquired resistance to MET TKIs through progressive exposure to the drug will help to identify such resistance mechanisms, as will the constitution of series of pre-and post-TKI tumor samples. On the other hand, MET exon 14 splice mutations may confer resistance to TKIs targeting other RTKs. Interestingly, a lung adenocarcinoma with an activating EGFR mutation and a T790M mutation has been reported to have a MET exon 14 splice mutation (42) . Although no details were provided in this case, it is reasonable to speculate that a mutation leading to MET exon 14 skipping might confer resistance to EGFR TKIs in EGFRmutant lung cancers because MET activation through MET amplification or HGF overexpression has already been shown to do so (99, 100) . Comparing tumor samples from EGFR-mutant lung cancer patients before and after EGFR TKI might reveal additional cases of involvement of a MET mutation in resistance to EGFR TKIs.
Conclusion
Altogether, these data strongly suggest that patients with a MET exon 14 mutation could benefit from TKI treatment. Although exon 14 skipping was identified two decades ago, not until two years ago was it detected in a large number of human tumor samples. Improved sequencing techniques and bioinformatic analyses will probably reveal other exon-skipping events in human diseases. In this line, investigators have recently evidenced an association of MET exon 14 splice mutations with a rare congenital osteofibrous dysplasia (OFD), using next-generation sequencing of chromosomal loci associated with the disease (101) . It is rather puzzling that these germline mutations drive a nonneoplastic autosomal-dominant disease with a limited phenotype not associated with higher rate of malignancies. It could be that a MET exon 14 splice mutation requires concomitant genomic alterations to drive lung cancer, as suggested by the frequent co-occurrence of MDM2 amplification. In the same study, strikingly, the researchers evidenced in another patient a MET Tyr1003 mutation. Further work is required to elucidate why these two MET alterations evidenced in cancers and conferring transforming ability to cells in vitro are associated with OFD.
Intriguingly, no skeletal development problems have ever been observed in mouse models with MET deficiency or overexpression.
Other alternative splicing events have recently been implicated in tumorigenesis. For example, an alternatively spliced isoform of the recepteur d'origine Nantais (RON), a MET-related receptor tyrosine kinase, has been found in pancreatic adenocarcinoma xenografts from patients and is associated with transforming capacity in vitro (102) . More generally, splicing factor 3b subunit 1, a component of the spliceosome, appears commonly to be mutated in various cancers; this may influence tumorigenesis via global alteration of splicing (103) . Further work is needed to identify the functional consequences and clinical impact of such events, as in the case of the MET exon 14 splice mutations.
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